Beyond cancer biology, DES(1-3) IGF-1 has been investigated in neuroprotection models, where its high potency and reduced IGFBP binding facilitate clean receptor activation in brain tissue preparations where IGFBP concentrations would otherwise limit native IGF-1 activity
10.1016/j.eurger.2010.08.001 160 KoradS.MndelT.PerryB
What you really need to know : stronger weight loss in trials doesnt mean everyone should rush in- screening , medical supervision, and long-term plan matter
It works as a thickener, emulsifier, and texture enhancer that gives gel-creams a silky, lightweight feel
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy: A Target Trial Emulation by Kamika R
"Lilly's Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges." December 12, 2025